Reversal of experimental renovascular hypertension restores coronary microvascular function and architecture

American Journal of Hypertension

Volumn 24, Issue 4, 2011, Pages 458-465

  Urbieta Caceres, Victor H ^a   Zhu, Xiang Yang ^a   Gibson, Matthew E ^a   Favreau, Frederic D ^a   Jordan, Kyra ^a   Lerman, Amir ^a   Lerman, Lilach O ^a  

^a MAYO CLINIC   (United States)

Author keywords

blood pressure; hypertension; microvascular dysfunction; remodeling; renovascular hypertension

Indexed keywords

ADENOSINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; FEMALE; FIBROSIS; FRACTIONAL FLOW RESERVE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HYPERTENSION; MALE; MICROVASCULARIZATION; NONHUMAN; OXYGEN SENSING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERMEABILITY; PRIORITY JOURNAL; RENAL ARTERY; RENOVASCULAR DISEASE; RENOVASCULAR HYPERTENSION; REVIEW; SHAM PROCEDURE; SYSTOLIC BLOOD PRESSURE;

ANGIOPLASTY; ANIMALS; CAPILLARY PERMEABILITY; FEMALE; HYPERTENSION, RENOVASCULAR; HYPERTROPHY, LEFT VENTRICULAR; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY; MICROVESSELS; PROCOLLAGEN-PROLINE DIOXYGENASE; RENAL ARTERY OBSTRUCTION; SWINE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 79952987942     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2010.259     Document Type: Review

References (41)

1. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370:591-603. (Pubitemid 47247855)
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli W P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566. (Pubitemid 20176696)
3. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35:580-586. (Pubitemid 30108152)
4. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104:1615-1621. (Pubitemid 32947523)
5. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54. (Pubitemid 28036154)
6. Kaneko K, Susic D, Nunez E, Frohlich ED. ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats. Am J Med Sci 1997; 314:21-27. (Pubitemid 27295033)
7. Nagano M, Higaki J, Mikami H, Nakamaru M, Higashimori K, Katahira K, Tabuchi Y, Moriguchi A, Nakamura F, Ogihara T. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens 1991; 9:595-599.
8. Peng H, Carretero OA, Liao TD, Peterson EL, Rhaleb NE. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension. Hypertension 2007; 49:695-703.
9. Peng H, Carretero OA, Vuljaj N, Liao TD, Motivala A, Peterson EL, Rhaleb NE. Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 2005; 112:2436-2445. (Pubitemid 41504493)
10. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90:2056-2069. (Pubitemid 24320959)
11. Rodriguez-Porcel M, Herrman J, Chade AR, Krier JD, Breen JF, Lerman A, Lerman LO. Long-term antioxidant intervention improves myocardial microvascular function in experimental hypertension. Hypertension 2004; 43:493-498. (Pubitemid 38174160)
12. Lin J, Zhu X, Chade AR, Jordan KL, Lavi R, Daghini E, Gibson ME, Guglielmotti A, Lerman A, Lerman LO. Monocyte chemoattractant proteins mediate myocardial microvascular dysfunction in swine renovascular hypertension. Arterioscler Thromb Vasc Biol 2009; 29:1810-1816.
13. Rodriguez-Porcel M, Lerman A, Herrmann J, Schwartz RS, Sawamura T, Condorelli M, Napoli C, Lerman LO. Hypertension exacerbates the effect of hypercholesterolemia on the myocardial microvasculature. Cardiovasc Res 2003; 58:213-221. (Pubitemid 36351640)
14. Rodriguez-Porcel M, Zhu XY, Chade AR, Amores-Arriaga B, Caplice NM, Ritman EL, Lerman A, Lerman LO. Functional and structural remodeling of the myocardial microvasculature in early experimental hypertension. Am J Physiol Heart Circ Physiol 2006; 290:H978-H984.
15. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356:830-840.
16. Zhu XY, Daghini E, Chade AR, Napoli C, Ritman EL, Lerman A, Lerman LO. Simvastatin prevents coronary microvascular remodeling in renovascular hypertensive pigs. J Am Soc Nephrol 2007; 18:1209-1217. (Pubitemid 46536907)
17. Sluimer JC, Kolodgie FD, Bijnens A P, Maxfield K, Pacheco E, Kutys B, Duimel H, Frederik PM, van Hinsbergh VW, Virmani R, Daemen MJ. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol 2009; 53:1517-1527.
18. Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram M, Nath KA, Holmes DR Jr, Lerman A. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001; 21:122-128. (Pubitemid 32061936)
19. Zhu XY, Daghini E, Chade AR, Rodriguez-Porcel M, Napoli C, Lerman A, Lerman LO. Role of oxidative stress in remodeling of the myocardial microcirculation in hypertension. Arterioscler Thromb Vasc Biol 2006; 26:1746-1752. (Pubitemid 44305327)
20. Favreau F, Zhu XY, Krier JD, Lin J, Warner L, Textor SC, Lerman LO. Revascularization of swine renal artery stenosis improves renal function but not the changes in vascular structure. Kidney Int 2010; 78:1110-1118.
21. Chade AR, Rodriguez-Porcel M, Herrmann J, Zhu X, Grande J P, Napoli C, Lerman A, Lerman LO. Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol 2004; 15:958-966. (Pubitemid 38375315)
22. Lerman LO, Schwartz RS, Grande J P, Sheedy PF, Romero JC. Noninvasive evaluation of a novel swine model of renal artery stenosis. J Am Soc Nephrol 1999; 10:1455-1465. (Pubitemid 29297520)
23. Chade AR, Krier JD, Rodriguez-Porcel M, Breen JF, McKusick MA, Lerman A, Lerman LO. Comparison of acute and chronic antioxidant interventions in experimental renovascular disease. Am J Physiol Renal Physiol 2004; 286: F1079-F1086. (Pubitemid 38656363)
24. Urbieta-Caceres VH, Lavi R, Zhu XY, Crane JA, Textor SC, Lerman A, Lerman LO. Early atherosclerosis aggravates the effect of renal artery stenosis on the swine kidney. Am J Physiol Renal Physiol 2010; 299:F135-F140.
25. Zhu XY, Chade AR, Rodriguez-Porcel M, Bentley MD, Ritman EL, Lerman A, Lerman LO. Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol 2004; 24:1854-1859. (Pubitemid 39350303)
26. Daghini E, Primak AN, Chade AR, Zhu X, Ritman EL, McCollough CH, Lerman LO. Evaluation of porcine myocardial microvascular permeability and fractional vascular volume using 64-slice helical computed tomography (CT). Invest Radiol 2007; 42:274-282. (Pubitemid 46558086)
27. Chade AR, Rodriguez-Porcel M, Grande J P, Zhu X, Sica V, Napoli C, Sawamura T, Textor SC, Lerman A, Lerman LO. Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. Arterioscler Thromb Vasc Biol 2003; 23:1295-1301. (Pubitemid 36871287)
28. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39:257-265. (Pubitemid 34084631)
29. Halcox J P, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106:653-658. (Pubitemid 34851922)
30. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104:2673-2678. (Pubitemid 33108132)
31. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-196. (Pubitemid 32655837)
32. Roman MJ, Alderman MH, Pickering TG, Pini R, Keating JO, Sealey JE, Devereux RB. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. Am J Hypertens 1998; 11:387-396. (Pubitemid 28238676)
33. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275:1507-1513. (Pubitemid 26140765)
34. Pipinos II, Nypaver TJ, Moshin SK, Careterro OA, Beierwaltes WH. Response to angiotensin inhibition in rats with sustained renovascular hypertension correlates with response to removing renal artery stenosis. J Vasc Surg 1998; 28:167-177. (Pubitemid 28347649)
35. Stulak JM, Lerman A, Caccitolo JA, Wilson SH, Romero JC, Schaff HV, Rodriguez Porcel M, Lerman LO. Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. Atherosclerosis 2001; 154:195-201. (Pubitemid 32008581)
36. Yamani MH, Massie BM. Hypertension, myocardial ischemia, and sudden death. Curr Opin Cardiol 1994; 9:542-550. (Pubitemid 24267778)
37. Yurenev A P, DeQuattro V, Dubov PB, Ostroumov EN, Nikulin IA, Konyaeva EB, Balyakina EV, Atachanov SE, Kosenko AI, Popov EG. Silent myocardial ischemia in patients with essential hypertension. Am J Hypertens 1992; 5:169S-174S.
38. Zhu XY, Rodriguez-Porcel M, Bentley MD, Chade AR, Sica V, Napoli C, Caplice N, Ritman EL, Lerman A, Lerman LO. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation 2004; 109:2109-2115. (Pubitemid 38620220)
39. Smith TG, Robbins PA, Ratcliffe PJ. The human side of hypoxia-inducible factor. Br J Haematol 2008; 141:325-334. (Pubitemid 351521147)
40. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294:1337-1340. (Pubitemid 33063099)
41. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim AV, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468-472. (Pubitemid 32335942)